The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s cardiac biomarkers testing market report forecasts the cardiac biomarkers testing market size to grow to $18.46 Billion by 2027, with a CAGR (compound annual growth rate) of more than 11%.

Learn More On The Cardiac Biomarkers Testing Market Report 2023 – https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

Cardiac Biomarkers Testing Market Size Forecast
The global cardiac biomarkers testing market is expected to grow from $10.83 billion in 2022 to $12.10 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cardiac biomarkers testing market size is expected to grow to $18.46 billion in 2027 at a CAGR of 11.1%.

North America held the largest cardiac biomarkers testing market share.

Key Cardiac Biomarkers Testing Market Driver ­– Increase In The Prevalence Of Cardiovascular Diseases
According to a report published by the American Heart Association, a non-profit organisation located in the United States dedicated to treating heart disease and stroke, cardiovascular disease (CVD) was responsible for approximately 19.1 million deaths worldwide in 2020. The age-adjusted death rate was 239.8 individuals per 100,000. 7354.1 per 100,000 was the age-adjusted prevalence rate. In 2020, the highest rates of CVD-related mortality were found in Eastern Europe and Central Asia. As a result, an increase in the prevalence of cardiovascular disorders is propelling the cardiac biomarkers testing market forward.

Request for A Sample Of The Global Cardiac Biomarkers Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

Key Cardiac Biomarkers Testing Market Trend – Product Innovations
To maintain their market position, major businesses in the cardiac biomarker testing market are focusing on producing innovative products. For example, Siemens Healthcare GmbH, a German medical technology business, will release the Atellica VTLi Patient-Side Immunoassay Analyzer in October 2021. The Atellica VTLi Patient-Side Immunoassay Analyzer is distinguished by its high-sensitivity troponin I test from a fingerstick sample. Clinicians and healthcare workers can improve patient outcomes by employing it to identify a heart attack quickly and reliably in eight minutes.

Cardiac Biomarkers Testing Market Segment
1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP and NT-proBNP), Ischemia Modified albumin (IMA), Other Biomarkers Types
2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications
3) By End-User: Hospitals, Specialty Clinics

Cardiac Biomarkers Testing Market Major Players and Strategies
Major players in the cardiac biomarkers testing market are Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company (BD), Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics, Merck KGaA, Beckman Coulter Inc., and QIAGEN N.V.

HyTest Invest Oy and its subsidiaries (“HyTest”) were acquired for an unknown sum in September 2021 by Shenzhen Mindray Bio-Medical Electronics Co. Ltd, a Chinese medical instruments producer. Mindray will have excellent R&D and innovation capabilities for raw materials as a result of this acquisition, which will help HyTest maintain its position as a world leader in the upstream IVD raw material industry by supporting its continued investment in R&D as well as strengthening and improving its core competitive edge. HyTest Ltd is a US-based supplier of antibodies and antigens for the IVD market, such as heart indicators, inflammation markers, tumour markers, and others.

The Cardiac Biomarkers Testing Global Market Report 2023 covers regional data on cardiac biomarkers testing market size, cardiac biomarkers testing market trends and drivers, opportunities, strategies, and cardiac biomarkers testing market competitor analysis. The countries covered in the cardiac biomarkers testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Cardiac biomarkers testing refers to tests that assess the levels of cardiac biomarkers in the blood. It is used to diagnose, assess, and monitor persons who may be suffering from acute coronary syndrome (ACS).

View More Reports Related To The Cardiac Biomarkers Testing Market –
Cardiac Assist Devices And Equipment Global Market Report 2023
Biomarkers Global Market Report 2023
Cardiac Pacemakers Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: